DE-LYCRA/DCC
9.5.2024 03:01:32 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative, sustainable solutions for the apparel and personal care industries, announced today that it has signed a letter of intent with Dairen Chemical Corporation (DCC) to convert QIRA®—the next generation of 1,4 butanediol (BDO)—into low-impact PTMEG, the main ingredient in patented bio-derived LYCRA® fiber. Dairen will be the first company in the world to mass produce this low-impact bio-PTMEG at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509462079/en/
Left to Right: Steve Stewart, chief brand and innovation officer, The LYCRA Company, and Shean-Tung Lin, Chairman, Dairen Chemical Corporation (DCC), sign a letter of intent for DCC to convert QIRA® into low-impact PTMEG for bio-derived LYCRA® fiber. (Photo: Business Wire)
In September 2022, The LYCRA Company and Qore® announced they were joining forces to enable the production of bio-derived LYCRA® fiber made with QIRA®. Now, DCC joins this distinctive collaboration, converting QIRA® into bio-PTMEG. This unique PTMEG will make up the renewable portion of LYCRA® fiber, accounting for 70% of the fiber’s content. It is being made exclusively for The LYCRA Company to its stringent specifications. With its low-impact allyl alcohol process, DCC has pioneered a technology that creates the lowest-impact PTMEG available, which is cleaner and has a lower carbon footprint than product produced with natural gas or coal.1
The LYCRA Company, Qore®, and DCC are united by a shared commitment to R&D, health and safety, sustainability, and conservation. To mark this event, Steve Stewart, The LYCRA Company’s chief brand and innovation officer, presented DCC with a Green Partner Award. The award acknowledges DCC’s ongoing sustainability efforts and commitment to creating low-impact products.
“Our collaboration heralds a brand-new era of environmentally conscious production activities, fueled by our shared commitment to reducing carbon footprints and developing world-leading eco-friendly solutions,” said DCC’s chairman, Lin Shean-Tung. “Sustainability is not merely a trend, but an imperative for the future of our planet. We are honored to receive the Green Partner Award and embark on this journey alongside The LYCRA Company, advancing sustainable practices in the industry.”
Available in early 2025, patented bio-derived LYCRA® fiber made with QIRA® will be the world’s first renewable spandex available on a large scale. By using annually renewable dent corn, an initial screening calculation indicates that the carbon footprint of LYCRA® fiber potentially could be reduced by up to 44 percent2 compared to LYCRA® fiber without bio-derived materials. Further, the fiber will offer equivalent performance to traditional LYCRA® fiber, making it an easy replacement for mills, brands and retailers.
“We are excited to collaborate with DCC to bring bio-derived LYCRA® fiber made with QIRA® to market and realize our shared vision for a more sustainable value chain,” said Stewart. “Given the combination of using bio-derived input from corn, plus conversion at a state-of-the-art QORE® facility run on wind power, and transformation to PTMEG using DCC’s low-impact process, we anticipate the potential for additional reductions as we go into production.”
For many years, Dairen has demonstrated its sustainability efforts in raw materials management, waste elimination, process enhancement, innovations, and more. It has also achieved significantly lower carbon emissions in its product offerings than its competition.
“Sustainability has evolved from fulfilling requirements to being a competitive advantage,” said Simon Chuang, vice president of global sourcing and procurement at The LYCRA Company. “We’re committed to selecting, promoting, and expanding our business with supply partners like DCC who embrace and drive meaningful sustainability efforts.”
Visit lycra.com/qira to learn more about bio-derived LYCRA® fiber made with QIRA®.
1Estimate from Cradle-to-Gate Screening PCF for a representative DAIREN PTMEG manufacturing facility, year 2023, prepared by DNV Business Assurance Co., Ltd.
2Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
About Qore® LLC
Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. Qore® and QIRA® are trademarks of Qore® LLC. For more information and inquiries visit https://www.myqira.com/.
About Dairen Chemical Corporation (DCC)
Founded in 1979, DCC is a leading maker of acetyl and allyl chemicals. The company board has been chaired by Mr. Lin Shean-Tung since June 2019. DCC operates seven production sites in Asia and serves customers in more than one hundred countries. Major products include Vinyl Acetate Monomer, Vinyl Acetate Ethylene (VAE) Emulsion, VAE Redispersible Powder, Allyl Alcohol, 1,4-Butanediol and PTMEG. Headquartered in Taipei, Taiwan, its productions sites are in Taiwan, China, Singapore and Malaysia. Under the leadership of Chairman Lin, DCC is expanding its international activities and enhancing its global presence.
LYCRA® is a trademark of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509462079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom